A cost-utility analysis of losartan versus atenolol in the treatment of mild to moderate hypertension

被引：1
|
作者：
Anis, AH
Sun, H
Singh, S
Woolcott, JC
Nosyk, B
机构：
[1] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
[2] Canadian HIV Trials Network, Vancouver, BC, Canada
[3] BC Ctr Dis Control, Vancouver, BC, Canada
来源：
VALUE IN HEALTH | 2004年 / 7卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)62383-2
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：323 / 323
页数：1
相关论文
共 50 条
  • [31] METOPROLOL OR ATENOLOL FOR MILD-TO-MODERATE HYPERTENSION
    LYNGSTAM, O
    RYDEN, L
    LANCET, 1979, 2 (8143): : 634 - 634
  • [32] COST-UTILITY OF USTEKINUMAB IN THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN COLOMBIA
    Ojeda, C.
    Hernandez, N.
    Giraldo, C., V
    Argote, A. C.
    Coronell, S.
    Roa, M.
    VALUE IN HEALTH, 2016, 19 (03) : A124 - A124
  • [33] COST-UTILITY OF USTEKINUMAB IN THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN COLOMBIA
    Aguirre, A.
    Guerrero, E.
    Hernandez, N.
    Coronell, S.
    Argote, A. C.
    Giraldo, C., V
    Ojeda, C.
    VALUE IN HEALTH, 2017, 20 (05) : A211 - A211
  • [34] Cost-utility of as-needed ICS-formoterol versus to maintenance ICS in mild to moderate persistent asthma
    Jefferson Antonio Buendía
    Diana Guerrero Patiño
    BMC Pulmonary Medicine, 21
  • [35] Cost-utility of as-needed ICS-formoterol versus to maintenance ICS in mild to moderate persistent asthma
    Buendia, Jefferson Antonio
    Patino, Diana Guerrero
    BMC PULMONARY MEDICINE, 2021, 21 (01)
  • [36] Cost-effectiveness of Losartan versus Atenolol in treating hypertension - An analysis of the LIFE study from a Swiss perspective
    Szucs, TD
    Burnier, M
    Erne, P
    CARDIOVASCULAR DRUGS AND THERAPY, 2004, 18 (05) : 391 - 397
  • [37] COST-UTILITY ANALYSIS OF VALSARTAN VERSUS VALSARTAN PLUS HYDROCHLOROTHIAZIDE IN PATIENTS WITH HYPERTENSION IN THE US
    Pednekar, P.
    VALUE IN HEALTH, 2018, 21 : S62 - S62
  • [38] Cost-Effectiveness of Losartan Versus Atenolol in Treating Hypertension—An Analysis of the LIFE Study from a Swiss Perspective
    Thomas D. Szucs
    Michel Burnier
    Paul Erne
    Cardiovascular Drugs and Therapy, 2004, 18 : 391 - 397
  • [39] COST-UTILITY ANALYSIS OF HUMAN URINARY KALLINDINOGENASE VERSUS 3-N-BUTYLPHTHALIDE FOR PATIENTS WITH MILD OR MODERATE ACUTE ISCHEMIC STROKE
    Guan, X.
    Zhang, Y.
    Li, H.
    VALUE IN HEALTH, 2020, 23 : S264 - S264
  • [40] Cost-utility analysis of Amevive™ (alefacept) in the treatment of patients with moderate-to-severe psoriasis
    Iskedjian, M
    Barkovsky, L
    Desjardins, O
    Walker, JH
    Dorkalam, M
    Shear, N
    Einarson, TR
    VALUE IN HEALTH, 2005, 8 (03) : 331 - 331
12345